Some Epidemiological Measures of Cancer in Kuwait: National Cancer Registry Data from 2000-2009

El-Basmy, A.,Al-Mohannadi, S.,Al-Awadi, A. Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.7

Introduction: Cancer is the second cause of death in Kuwaiti people after cardiovascular diseases. This study is the first in the country to describe epidemiological measures related to cancer in this population. Methods: Data obtained from the Kuwait cancer registry included all Kuwaiti patients between years 2000-2009. Analyses were conducted using age-specific rates, the age-standardization-direct method, 95% confidence intervals (95% CI), cumulative risk by the age of 74 years, limited-duration prevalence, mortality and forecasting to year 2029. Results: It was noted that the commonest cancer sites were colorectal with an age standardized incidence rate (ASIR) of 16.1/100,000 in males and breast (49.4/100,000) in the female population. The trend of cancer incidence (1974-2009) showed no statistically significant change. First causes of death due to cancer were female breast 8(6.4-9.6)/100,000 and lung (males) 8.1/100,000 (6.6-10.0). The risk of developing cancer by the age of 74 was 13.4% (1/8) and 14.3% (1/7) in males and females respectively, and the risk of dying from cancer in the same age group was 1/17 and 1/23. By the end of 2009, prevalent cases represented 0.52% of the Kuwaiti population. In the year 2029, the total number of cancer cases is expected to reach 1200 cases compared to 889 cases in 2009. Conclusions and recommendations: The most common cancers in Kuwait (breast, colorectal and lung) are largely preventable. Prompt and effective interventional prevention programs that vigorously involve diet, anti-smoking and physical activity for both sexes are urgently required.

Profile of Lung Cancer in Kuwait

El-Basmy, Amani,Al-Mohannadi, Shihab,Al-Awadi, Ahmed Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.10

Background: Lung cancer is the most frequent cancer in males and the fourth most frequent site in females, worldwide. This study is the first to explore the profile of lung cancer in Kuwait. Materials and Methods: Cases of primary lung cancer (Kuwaiti) in Kuwait cancer Registry (KCR) were grouped in 4 periods (10 years each) from 1970-2009. Epidemiological measures; age standardized incidence rate (ASIR) with 95% confidence intervals (CI), Standardized rate ratio (SRR) and Cumulative risk and Forecasting to year 2020-2029 used for analysis. Results: Between years, 2000-2009 lung cancer ranked the 4th and the 9th most frequent cancer in males and females respectively. M:F ratio 1:3. Mean age at diagnosis (95%CI) was 65.2 (63.9-66.4) years. The estimated risk of developing lung cancer before the age of 75 years in males is 1.8% (1/56), and 0.6 (1/167) in females. The ASIR for male cases was 11.7, 17.1, 17.0, 14.0 cases/100,000 population in the seventies, eighties, nineties and in 2000-2009 respectively. Female ASIR was 2.3, 8.4, 5.1, 4.4 cases/100,000 population in the same duration. Lung cancer is the leading cause cancer death in males 168 (14.2%) and the fifth cause of death due to cancer in females accounting for 6.1% of all cancer deaths. The ASMR (95%CI) was 8.1 (6.6-10.0) deaths/100,000 population and 2.8 (1.3-4.3) deaths/100,000 population in males and females respectively. The estimated Mortality to incidence Ratio was 0.6. Conclusions: The incidence of lung cancer between years 2000-2009 is not different from that reported in the seventies. KCR is expecting the number of lung cancer cases to increase.

Camel Milk as an Adjuvant Therapy for the Treatment of Type 1 Diabetes: Verification of a Traditional Ethnomedical Practice

Ragaa Hosny Mohamad,Zekry Khalid Zekry,Hussain A. Al-Mehdar,Omar Salama,Siad Ebrahim El-Shaieb,Amany A. El-Basmy,Mohamad Gamil Abdel Monem Al-said,Sabry Mohamed Sharawy 한국식품영양과학회 2009 Journal of medicinal food Vol.12 No.2

There is a traditional belief in the Middle East that regular consumption of camel milk may aid in prevention and control of diabetes. The aim of this work was to evaluate the efficacy of camel milk as an adjuvant therapy in young type 1 diabetics. This 16-week randomized study enrolled 54 type 1 diabetic patients (average age 20 years) selected from those attending the outpatient diabetes clinic of the Menofia University Hospital, affiliated with Egypt's National Cancer Institute. Subjects were randomly divided into two groups of 27 patients: one received usual management (diet, exercise, and insulin), whereas the other received 500 mL of camel milk daily in addition to standard management. A control group of 10 healthy subjects was also assessed. The following parameters were evaluated at baseline and at 4 and 16 weeks: hemoglobin A1c (HbA1c), human C-peptide, lipid profile, serum insulin, anti-insulin antibodies, creatinine clearance, albumin in 24-hour urine, body mass index, and Diabetes Quality of Life score. The following parameters were significantly different between the usual-management group versus the camel milk group after 16 weeks: fasting blood sugar (227.2 ± 17.7 vs. 98.9 ± 16.2 mg/dL), HbA1c (9.59 ± 2.05[%] vs. 7.16 ± 1.84[%]), serum anti-insulin antibodies (26.20 ± 7.69 vs. 20.92 ± 5.45 μU/mL), urinary albumin excretion (25.17 ± 5.43 vs. 14.54 ± 5.62 mg/dL/24 hours), daily insulin dose (48.1 ± 6.95 vs. 23 ± 4.05 units), and body mass index (18.43 ± 3.59 vs. 24.3 ± 2.95 kg/m2). Most notably, C-peptide levels were markedly higher in the camel milk group (0.28 ± 0.6 vs. 2.30 ± 0.51 pmol/mL). These results suggest that, as an adjunct to standard management, daily ingestion of camel milk can aid metabolic control in young type 1 diabetics, at least in part by boosting endogenous insulin secretion.

Camel Milk as an Adjuvant Therapy for the Treatment of Type 1 Diabetes: Verification of a Traditional Ethnomedical Practice

Al-Tahtawy, Ragaa Hosny Mohamad,Zekry, Zekry Khalid,Al-Mehdar, Hussain A.,Salama, Omar,El-Shaieb, Siad Ebrahim,El-Basmy, Amany A.,Al-said, Mohamad Gamil Abdel Monem,Sharawy, Sabry Mohamed The Korean Society of Food Science and Nutrition 2009 Journal of medicinal food Vol.12 No.2

There is a traditional belief in the Middle East that regular consumption of camel milk may aid in prevention and control of diabetes. The aim of this work was to evaluate the efficacy of camel milk as an adjuvant therapy in young type 1 diabetics. This 16-week randomized study enrolled 54 type 1 diabetic patients (average age 20 years) selected from those attending the outpatient diabetes clinic of the Menofia University Hospital, affiliated with Egypt's National Cancer Institute. Subjects were randomly divided into two groups of 27 patients: one received usual management (diet, exercise, and insulin), whereas the other received 500 mL of camel milk daily in addition to standard management. A control group of 10 healthy subjects was also assessed. The following parameters were evaluated at baseline and at 4 and 16 weeks: hemoglobin A1c (HbA1c), human C-peptide, lipid profile, serum insulin, anti-insulin antibodies, creatinine clearance, albumin in 24-hour urine, body mass index, and Diabetes Quality of Life score. The following parameters were significantly different between the usual-management group versus the camel milk group after 16 weeks: fasting blood sugar ($227.2\;{\pm}\;17.7$ vs. $98.9\;{\pm}\;16.2\;mg/dL$), HbA1c ($9.59\;{\pm}\;2.05$[%] vs. $7.16\;{\pm}\;1.84$[%]), serum anti-insulin antibodies ($26.20\;{\pm}\;7.69$ vs. $20.92\;{\pm}\;5.45\;{\mu}U/mL$), urinary albumin excretion ($25.17\;{\pm}\;5.43$ vs. $14.54\;{\pm}\;5.62\;mg/dL$/24 hours), daily insulin dose ($48.1\;{\pm}\;6.95$ vs. $23\;{\pm}\;4.05$ units), and body mass index ($18.43\;{\pm}\;3.59$ vs. $24.3\;{\pm}\;2.95\;kg/m^2$). Most notably, C-peptide levels were markedly higher in the camel milk group ($0.28\;{\pm}\;0.6$ vs. $2.30\;{\pm}\;0.51\;pmol/mL$). These results suggest that, as an adjunct to standard management, daily ingestion of camel milk can aid metabolic control in young type 1 diabetics, at least in part by boosting endogenous insulin secretion.